Business Overview - Elutia sold its BioEnvelope business to Boston Scientific for $88 million [11, 59] - The BioEnvelope business financials are now reported as "Discontinued Operations" [60] - Elutia is targeting the $1.5 billion breast reconstruction market with its technology platform [14, 17, 18, 70] Market Opportunity - Biologics represent 65% of the $1.5 billion US breast reconstruction market [18, 19, 20] - Biologic mesh is used in over 90% of breast reconstruction cases [20] - 15-20% of breast reconstruction patients experience infection [17, 22] - The average economic cost to the hospital of breast reconstruction infection is $48,344 [23] Financial Performance - Q3 2025 net sales were $3.3 million compared to $3.6 million in Q3 2024 [68] - Q3 2025 GAAP gross margin was 55.8% compared to 48.9% in Q3 2024 [68] - Q3 2025 adjusted gross margin was 63.9% compared to 56.3% in Q3 2024 [68] - The company received $49 million in cash at closing from the BioEnvelope sale, net of expenses and debt repayment [68] - The estimated liability of the remaining 6 FiberCel litigation cases is $0.7 million [68]
Elutia(ELUT) - 2025 Q3 - Earnings Call Presentation